Don Apanovitch

Board Member

Senior director with over 25 years of experience overseeing of comprehensive drug discovery development and downstream target validation using functional genomics, MOA, and phenotypic 2D and 3D high content imaging assays and screens. Highly experienced, with over 20 years, in using different therapeutic disease, tumor, adaptive and innate immune cellular models for use in a screening or target validation strategies with High Content imaging and other innovative assay readouts.